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Alterations of blood flow patterns strongly correlate with arterial wall diseases
such as atherosclerosis and aneurysm. Here, a simple, pumpless, close-loop,
easy-to-replicate, and miniaturized flow device is introduced to concurrently
expose 3D engineered vascular smooth muscle tissues to high-velocity
pulsatile flow versus low-velocity disturbed flow conditions. Two flow regimes
are distinguished, one that promotes elastin and impairs collagen I assembly,
while the other impairs elastin and promotes collagen assembly. This latter
extracellular matrix (ECM) composition shares characteristics with
aneurysmal or atherosclerotic tissue phenotypes, thus recapitulating crucial
hallmarks of flow-induced tissue morphogenesis in vessel walls. It is shown
that the mRNA levels of ECM of collagens and elastin are not affected by the
differential flow conditions. Instead, the differential gene expression of matrix
metalloproteinase (MMP) and their inhibitors (TIMPs) is flow-dependent, and
thus drives the alterations in ECM composition. In further support, treatment
with doxycycline, an MMP inhibitor and a clinically used drug to treat vascular
diseases, halts the effect of low-velocity flow on the ECM remodeling. This
illustrates how the platform can be exploited for drug efficacy studies by
providing crucial mechanistic insights into how different therapeutic
interventions may affect tissue growth and ECM assembly.
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Atherosclerosis and aneurysms represent
life-threatening pathological changes of the
arterial wall,[1,2] and are associated with sub-
stantial morbidity and mortality caused by
vessel rupture, hemorrhage, thromboem-
bolism, ischemic events, and even leading
to sudden death.[3] Pathological vessel wall
transformations are progressive and a re-
gression of these conditions with noninva-
sive interventions is not easy to achieve. For
instance, when pathological changes lead-
ing to aneurysm start to form, alterations
in blood flow gradually weaken the arterial
walls and cause progressive vessel expan-
sion and finally aneurysmal wall rupture.
Therefore, preventive interventional thera-
pies are the primary choice of treatment.[4]
In order to improve on early diagnosis
and therapy, significant challenges remain
to understand the underlying mechanisms.
Indeed, alterations in flow patterns (e.g.,
swirling flow, turbulent flow, or low veloc-
ity flow) lead to changes in stresses on the
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vessel wall.[1] These changes induce modifications and damage
of endothelial cells (ECs),[1,5] specifically at arterial branches,
where the blood flow patterns are disturbed rather than lam-
inar. Interestingly, it has been shown that the short exposure
of confluent EC monolayers (3 h) to disturbed flow in a coin-
plate device stimulated substantial cell retraction and cell loss
in vitro.[6,7] Even though 2D cell culture studies revealed some
of the underlying mechanisms of how pulsatile flow is sensed
by ECs,[8,9] far less is know about how the underlying smooth
muscle cells (SMCs) respond to flow exposure by remodeling
their extracellular matrix (ECM) once the EC layer is ruptured
due to disturbed flow in vascular bifurcations and sharp bends.
Collagens (mainly types I, III, IV, V, and VI) and the most
abundant type I collagen are highly expressed and assembled
into fibrillar networks in diseased arteries compared to normal
arteries.[10,11] In contrast, mature elastin fibers that have a half-
life time extending to many years in humans get degraded in dis-
eased artery walls,[12–14] therefore affecting the mechanical prop-
erties of vessel walls. Although, these changes have been re-
ported in humans and in animal models, a suitable human cell-
based 3D in vitro model to simultaneously grow diseased and
healthy vessel wall and to study de novo tissue morphogenesis
has not yet been introduced.[5,15,16]
Although several fluidic devices were previously used to study
the cell responses to flow shear stress,[15–18] to the best of our
knowledge, none of them exposed de novo grown 3D SMCs
tissues to physiologically relevant pulsatile shear flow conditions
using a simple device. While biomimetic bioreactors driven by
pulsatile pumps require complex and costly setups with limited
sample throughput, we established here a simple, pumpless,
close-loop, easy-to-replicate orbital shaker platform capable of
creating shear stresses on single bioengineered tissue. In con-
trast to prior orbital shaker cell culturing models[19,20] in which
the cells were seeded on the bottom of culture dishes in plane for-
mat (2D) and were exposed to the flow at the bottom of the dish,
we mounted here a tissue-engineered 3D polymeric scaffold per-
pendicular to the flow direction (Figure 1a; Figure S1a, Support-
ing Information). To set up our 3D tissue-engineered grafts, we
exploited protocols developed in the context of tissue-engineered
valvular and vascular constructs that are now in preclinical trials
by using biodegradable polyglycolic-poly(4-hydroxybutyric acid)
(PGA-P4HB) scaffolds.[21,22] These 3D scaffold flaps were then
mounted to the vertical dishwall and seededwith primary human
SMCswith the aid of fibrinogen. The tissues were exposed to pul-
satile flow as driven by the orbital shaker motion. As the concave
side of the tissue faced the flow, a secondary complicated flowwas
created at the backside of the tissue flap.
Since the positions of disturbed blood flow region have
been correlated with the development of atherosclerotic and
aneurysms[23] and associated with alteration of elastin and
collagens,[11,24,25] we evaluated the effects of flow on ECM
formation and composition. Our device revealed that lack of
pulsatile flow with association of low shear stress flow has a
major influence on pathological-like transformations of the ECM
in these de novo grown tissues, as it increased the collagen and
decreased the elastin content. In contrast, pulsatile high shear
stress flows on the side facing to predominantly laminar flow
that resembles healthy vessel wall. Since prior in vivo studies
showed that ECM remodeling is mediated by matrix metallopro-
teinase (MMP),[13,25–27] MMP inhibitors were studied extensively
to stop or slow down aneurysm and atherosclerosis progression
with limited success.[28] We, therefore, investigated the roles of
various counterbalancing MMPs and TIMPs in adjusting the
collagen III/I ratio and the collagen-to-elastin balance in this
model. To illustrate the utility of this device for drug screening,
we applied doxycycline, an MMP inhibitor used in clinical trials
to treat aneurysmal wall pathologies, and we show that it can halt
the damaging effect of the low flow velocity regime on ECM re-
modeling. The data suggest for the first time why doxycycline has
shown limited therapeutic efficacy in the clinic; because of its role
in altering the collagen I, III, and elastin balance.
2. Results
2.1. Device Setup and Quantification of the Pulsatile Flow
Patterns
The rotation of the orbital shaker creates a traveling wave of
fluid, which is sloshing around the center of the dish (Figure 1a;
Movie S1, Supporting Information). Even though orbital shak-
ers were used extensively to study the impact of flow on cells lo-
cated at the bottom of dishes,[20] the central element of our or-
bital shaker platform is that we mounted the tissue scaffolds per-
pendicular to the bottom of the dish. Therefore, one end of the
scaffold was fixed to the dish wall and the other end was post-
positioned about 1 cm toward the center of the dish as sketched
in Figure 1 and Figure S1a, Supporting Information. To create
our device, we proceeded as follows: i) mounting of the bio-
engineered PGA-P4HB microfibrillar porous scaffold (18 mm ×
5 mm × 1 mm) to the dish wall; ii) seeding of a suspension of
SMCs in a fibrinogen-thrombin precursor[29] into the mounted
porous scaffold in order to create a provisional 3D tissue follow-
ing an established prior clinical protocol;[22] and iii) after a day
of culture under static condition, exposing the tissue to pulsatile
flow using an orbital shaker platform for 3 weeks.
To estimate the flow profiles on the XY plane of our open
dish configuration, particularly around the tissue scaffold during
each cycle, we used a combination of experimental and computa-
tional approaches to characterize the local flow profiles (Figure 1)
and the flow-induced stress (Figure 2). We used laser light sheet
illumination and imaged fluorescent tracer particles (38–45 µm
in diameter) suspended in the medium. With the aid of a high-
speed camera, we tracked the flow near the front of the tissue
experimentally using particle trajectories in the medium (Fig-
ure 1b). In a dish without the tissue, the tangential flow in the
vicinity of the side wall was laminar and pulsatile (Movie S1 and
Figure S1b, Supporting Information), as shown previously.[20] In
the presence of the tissue scaffold, complex horizontal (XY) flow
patterns emerged, with mostly a laminar flow forming in the
front of the tissue, and a secondary lower velocity disturbed flow
at the back of the scaffold (Figure 1b; Movie S2, Supporting In-
formation). To further quantify the time-resolved flow conditions
in 3D, we used the commercial ANSYS Fluent software package
(ANSYS, Inc., Canonsburg, PA, USA) for computational fluid dy-
namics (CFD) modeling inside the orbitally shaken petri dish.
We employed the commonly used k − ϵ turbulence model to
simulate turbulent flow,[30] where k represents the turbulent
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Figure 1. Mounting of an engineered tissue scaffold in the orbital shaker dish platform together with the CFD analysis of the oscillatory traveling wave.
a) Actual image of the petri dish with a drop of ink (image inset, red arrow) to illustrate the fluid motion (Movie S4, Supporting Information), and two
schemes to show how the rectangular tissue scaffold made from biodegradable PGA-P4HB is mounted in the dish, together with defining the three
coordinates used in later figures. The tissue scaffold was attached with one end to the dish wall and with the other end to an upright post, located
1 cm away from the wall, thereby creating a convexly curved barrier facing the flow direction. b) The horizontal (XY) trajectories of particles (compiled
sequence of five images sequentially colored in rainbow colors) were visualized by short exposure (25 ms) with the aid of a high-speed camera. The
lengths of the experimental particle trajectories were used to calculate the corresponding velocities in the encircled region (as marked by the red line).
Scale bars 5 mm. c) To validate the CFD calculations, the time-resolved experimentally calculated horizontal velocities (dots) during three cycles in front
of the tissue are shown to be in good agreement with the average flow velocities as obtained by CFD. d) Fluctuations of shear stresses on one spot at
centroid of flap and e) average of wall shear stress along a horizontal curve on the frontside (blue line) and backside (red line) of flap in a cycle.
kinetic energy and ϵ is the turbulent dissipation to solve the tur-
bulent flow.While the fluids, that is, water and air inside the petri
dish, are initially at rest, it takes around six cycles of simulations
until the flow reaches the periodic condition for which the results
are given (Figure 1c,d,e; Movie S3, Supporting Information). In
order to validate the numerical data obtained from the simula-
tions, average horizontal (XY) velocity magnitudes in the front of
the flap (encircled red in Figure 1b) are calculated and then com-
pared with the experimental horizontal (XY) velocity data taken in
the same region from particle trajectory measurements. The av-
erage velocities in the front of the flap ranged from 5 to 17 cm s−1
within a cycle as calculated from the encircled area, which is in
the range of flow velocities found near the wall of small arteries,
for example, intracranial arteries.[31] In contrast, the average ve-
locities in the back of the flap ranged from 0.5 to 5 cm s−1. We
then used the CFD model to calculate the fluctuations of shear
stresses on the centroid region of the front and backside of the
flap, respectively (Figure 1d). The data indicate that the shear
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Figure 2. Experimental trajectories and computationally calculated velocities in horizontal (XY) plane beside horizontal and vertical shear stresses on
the flap surface. a) Trajectories of particles visualized in four snapshots of the oscillatory cycle taken with an exposure time of 2 ms. Scale bar 5 mm.
b) A snapshot of flow velocities from CFD simulations (see also Movie S4, Supporting Information). CFD analysis of shear stress tangential to the flap’s
curved surface in horizontal and vertical directions on the c) backside and d) frontside, respectively. The left sides of the rectangles are in contact with
the dish wall and the right sides are pointing towards the center of dish (see also Movies S5–S8, Supporting Information).
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Figure 3. Differential 𝛼-SMA content of de novo grown engineered tissues that faced either the high-velocity or the low-velocity pulsatile flow after
21 days of culture. a) Representative images of tissue sections that faced the high (front) versus low (back) flow velocity, respectively, immunostained
for 𝛼-SMA (red) and nuclei (blue). b) Corresponding pixel-by-pixel analyses normalized to nuclei counts revealed higher presentation of 𝛼-SMA-positive
cells on side facing the high flow velocity. Minimum three images from a triplicate experiment were analyzed. Scale bar 50 µm. Statistics were calculated
by one-way ANOVA and Bonferroni post hoc test.
stresses experienced in the frontside of the flap are an order of
magnitude higher than in the back, reaching a maximum of 1.3
versus 0.16 Pa, respectively. Moreover, the average shear stress
during one cycle and along the flap was extracted (Figure 1e).
The results show that the highest average shear stress in a cy-
cle is felt at the middle of the flap and slightly decreases towards
the two ends. On the backside, the shear stresses do not change
significantly along the flap.
To visualize the flow around the dish and the obstructing tis-
sue flap, we rendered Movie S3, Supporting Information, as ob-
tained from CFD. The four snapshots, which correspond to four
multi-stack images that were taken by a high-speed camera (Fig-
ure 2a,b), provide the experimental horizontal flow velocities and
vectorial directions in each of the quarters of an orbital motion
cycle. They illustrate that the running wave shortly hits the flap,
then runs parallel to the flap in horizontal plane, thereafter de-
parts toward the center of the dish together with the correspond-
ing CFD snapshots of wall shear stress (Figure 2c,d). While the
normalmotion of flow could not be resolved from the particle tra-
jectories, we separately analyzed the horizontal and vertical shear
stress values to the dish plane from the CFD simulations (hori-
zontal direction, Movies S5, S6 and Z direction, Movies S7, S8 in
the front and back, respectively, Supporting Information). This
analysis shows that the highest shear stresses are created in hor-
izontal direction (parallel to XY plane) in the front, with a short
vertical switch as the traveling wave hits the flap. The backside
is generally exposed to significantly lower shear stress values in
both horizontal and vertical directions.
2.2. 𝜶-SMA Expression Is Enhanced at the Frontside
of the Scaffold
To increase the physiological relevance of our study, primary vas-
cular SMCs were harvested from human vena saphenous magna
vein of donors (healthy volunteer women, 40–60 years old) and
were expanded.[32] As describe before, vascular SMCs are tran-
sitioning to a fibroblastic phenotype in typical 2D cell culture,
thus loosing SMC-specific biomarkers such as 𝛼-smooth muscle
actin (𝛼-SMA) during expansion[33] (Figure S2, Supporting
Information). It is indeed known that vascular SMCs maintain
significant phenotypic plasticity in contrast to terminally differ-
entiated cells.[15] Also in response to injury and inflammatory
disease, for example, atherosclerosis, vascular SMCs undergo
phenotypic modulation, characterized by decreased contractile
marker expression.[33,34] The transition of these SMCs to a fibrob-
lastic phenotype is, thus, partially reversible. We found that these
cells significantly upregulated 𝛼-SMA expression after 21 days
in culture when exposed to pulsatile flow conditions (Figure 3a).
When facing the high-velocity flow, immunostaining revealed
1.7 times higher levels of 𝛼-SMA (Figure 3b) as well as 1.5-fold
increase in 𝛼-SMA gene expression compared to the disturbed
flow. This indicates a significant redifferentiation of the cells
towards a SMC phenotype in the frontside compared to backside.
We, thus, refer to them as vascular SMCs in this manuscript.
2.3. ECM Elastin Assembly Was Enhanced at the Frontside, While
the Collagen I ECM Content Was Enhanced on the Backside
Since diseased vessel walls are typically seen in regions of
disturbed low velocity blood flow,[23] such as atherosclerotic and
aneurysm and associated with alteration of arterial wall ECM
proteins, for example, elastin and collagens,[10,24–26] we evaluated
the effect of flow on ECM assembly in the front and backsides
of our tissue flaps. First, we assessed the total collagens (all
isoforms of collagens) and elastin content on both sides of the
tissues (plane XY, Figure 1a) by biochemical assay (Figure 4a,b).
To quantify the levels of collagens and elastin, we used the pre-
viously validated Sircol and Fastin reagents and protocols.[35–37]
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By biochemical extraction, we measured significantly higher
collagen levels in the tissues’ backside (Figure 4a), and vice
versa, higher elastin levels in the tissues facing the high-velocity
flow (Figure 4b). Moreover, the matrix composition, including
collagen I, III, and elastin, as assembled by the cells in the front
and back was assessed by immunofluorescence staining. As
we used identical imaging setups to analyze endpoint stains
of the front and backside, pixel-by-pixel intensity analysis was
employed to compare the relative protein assembly on each side.
To visualize the fibronectin matrix, fluorescently labeled human
plasma fibronectin was supplemented to the culture medium, as
described previously,[38–40] over the entire tissue culture with ev-
ery medium exchange. The labeled fibronectin is then harvested
by the cells and incorporated into their native ECM fibrils. As
the tissue surfaces were uneven, labeled fibronectin was used as
positional reference to also locate other ECM proteins as visu-
alized in Figure S3, Supporting Information. Quantification of
collagen I via immunostaining revealed a significant relative de-
crease of collagen I matrix in the front compared to the backside
(Figure 4c,e; Figures S4 and S5, Supporting Information), and in
agreement with the trends derived from the biochemical assay
of collagen (Figure 4a). In contrast, we did not detect any relative
difference for collagen III between the front and backsides of the
tissues (Figures S4, S5, and S11, Supporting Information). Cross-
sectional collagen I and elastin images (Figure 4e,f) also showed
that the ECM mostly formed toward the tissue surfaces, likely
because of better nutrient perfusion besides the same trend
of asymmetrical ECM deposition was observed. In contrast,
mRNA analysis shows about equal COL1A1 gene expression
on both sides of the flap. Only the expression of COL2A1 and
COL3A1 is significantly upregulated in the front versus back
(Figure 4g).
For elastin, we see increased deposition only in the frontside
(Figure 4b,d,f; Figure S6, Supporting Information), while the
backside has little elastin content. This reflects well what is
seen in vivo where an elastin-rich ECM is a hallmark of healthy
arteries,[41] while the absence of elastin is found in degenerated
ECM of disease arteries.[13] In contrast to the analysis of ECM
content, we did not see any differential gene expression of elastin
(ELN) in the front versus the back. Since prior studies showed
that fibronectin promotes elastin deposition[42] and facilitates
the assembly of fibrillin-1[43] that also promotes the assembly of
elastin,[44] we examine the gene expression of fibronectin (FN)
and fibrillin-1 (FBN-1) in the front and backsides, and found 4.4-
fold and 7.8-fold increases in gene expression of FN and FBN-
1, respectively. These findings suggest a relatively higher elastin
fiber assembly in the frontside, despite the equal expression of
tropoelastin, is promoted by higher expression and assembly of
FN and FBN-1. Furthermore, we performed cell nuclei density
analyses on each side and found a slight increase (1.3-fold, p =
0.04) in cell density on the backside (Figure S7, Supporting In-
formation) and a significant increase of cell nuclei density in dy-
namically cultured tissues compared to static condition (twofold,
p < 0.001). However, cell density alone does not explain differen-
tial ECM assembly in this model.
To see whether collagen and elastin asymmetric assembly is
restricted to our specific cell type, we repeated the same experi-
ment with primary SMCs from another human donor and with
SMCs from sheep and observed similar differential flow effect on
relative ECM depositions in the front and the backsides of tissues
(Figures S5c,d and S6b,c, Supporting Information).
2.4. TIMP 1–3 Was Upregulated in the Front, But Not the
Backside, Thus Inhibiting Proteolytic MMP Activity
To reconcile the differences between the observed ECM depo-
sition as quantified by immunostaining and/or biochemical as-
says and the transcription mRNA levels of ECM proteins, we
asked whether tissue metalloproteinase (MMPs) and their in-
hibitors (TIMPs) play a role in the ECM remodeling as observed
here. Prior studies have described the role of MMPs and TIMPs
in aneurysm progression, rupture,[28,45] and atherosclerosis[46]
showing the importance of these regulators in vascular pathology.
TIMPs members also have been shown to inhibit several disin-
tegrin metalloproteinase (ADAMs). Particularly TIMP-3 acts as
inhibitor of the procollagen N-proteinase (ADAMTS-2) and is
therefore a key regulator of collagen fibrillogenesis.[47,48] To see
how the MMPs-TIMPs balance might affect our 3D model tis-
sues, we conducted RT-PCR analyses of mRNA isolated from
each side (exposed to different flow conditions) after 3 weeks
of culture (N = 3). We found that the mRNA expression of
MMPs in general was not significantly affected in the front
versus the backside (Figure 5a). In contrast, TIMP 1 and 3
showed a significant upregulation in the front versus backside
(Figure 5a).
To further assess the total protease activity of cells on each side
of the bioengineered 3D vascular wall, we checked fibrin degrada-
tion as an indirect indicator for protease activity[46] by immunos-
taining and comparative signal intensity analysis (Figure 5b,c;
Figure S8, Supporting Information). In comparison to the front,
we observed higher fibrin degradation, indicating a higher pro-
tease activity rate at the backside. These findings suggest that
the pulsatile laminar flow in the front shifts the MMPs/TIMPs
Figure 4. Differential deposition of collagen I and elastin in the front and backsides of the engineered tissues. The timeline summarizes how the samples
have been treated from cell seeding to the analysis. a) Total acid-pepsin soluble collagen and b) elastin concentrations were measured by biochemical
assays (Sircol and Fastin, respectively) in tissues harvested from either the front or the backsides. Representative stack maximum projection intensity
images of the front and backsides of tissues, which were immunostained after 3 weeks in culture for c) collagen I (magenta) and d) elastin (red). The
corresponding single-channel images are shown in Figure S2, Supporting Information. The coordinates in images are defined according to Figure 1. The
outer surface layers contacting the medium used for the analyses were ≈50 µm thick. Their protein contents were assessed by comparative pixel-by-pixel
intensity analysis of the respective immunostained images. Fibronectin was visualized not by immunostaining, but by supplementing labeled Alexa Flour
488 human plasma fibronectin (green) to the cell culture medium.[38] Cross-sectional views show the assembly of fibronectin, collagen I (e) and elastin
(d) on the surface and inside the tissues. g) Relative mRNA analysis of collagens (COL1A, COL2A1, and COL3A1), elastin (ELN) at day 21. Number of
biological replicates was 3 and ≥5 images were analyzed per replicate. Statistics were calculated by one-way ANOVA, Bonferroni post-hoc test. Scale bars
c,d) 50 µm and e,f) 200 µm. See also Figures S4–S6, Supporting Information, for single-stack confocal images of collagen I, III, and elastin, respectively.
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Figure 5. Differential mRNA levels and comparative immunostainings of the fibrin revealed that pulsatile high-velocity flow on frontside decreased the
overall MMP activity in engineered SMCs tissues by inhibiting their activity via TIMPs after 21 days in culture and doxycycline inhibit the fibrin remodeling
by inhibition of MMPs. a) Relative mRNA expression of metalloproteinase inhibitors (TIMP1, 2, and 3) and MMP (MMP 2, 9, 12, 14, and 15) at the
frontside versus backside. b) Comparative confocal microscopy and c) pixel-by-pixel intensity analysis of images showed delayed degradation of fibrin
in the tissue’s front versus backside in the absence or presence of doxycycline (10 µg mL−1). Fibronectin was visualized not by immunostaining, but
by supplementing labeled Alexa Flour 488 human plasma fibronectin (green) to the cell culture medium.[38] Number of biological replicates was 3, ≥5
images were analyzed per replicate. Flow diagram shows how the samples have been treated during the culturing period. Scale bars 50 µm. See also
Figures S8 and S9, Supporting Information, for respective single channel and cross-sectional confocal images.
balance in favor of protecting the ECM of the de novo grown
SMCs tissues, by inhibiting the proteolytic activity of the SMCs.
2.5. Doxycycline, a Controversial Clinical MMPs Inhibitor,
Prevents ECM Degradation and Remodeling under Disturbed
Pulsatile Flow
In a proof-of-concept study, we asked whether our platform is
suitable to gain insight into the efficacy of drugs on 3D tissues
grown from human cells. Thus, we investigate the effect of doxy-
cycline, a general MMP inhibitor,[49] yet controversial drug that
has been used in clinical trials to treat aneurysm and other vascu-
lar diseases.[50–52] While doxycycline-treated tissues are exposed
to flow in in vivomodels, all in vitro tests were performed in static
cell culture models,[53,54] and the drug was never tested in a dy-
namic in vitro model to the best of our knowledge. To further
clarify the role of MMPs, we thus assessed the efficacy of doxycy-
cline on ECM remodeling by SMCs and asked how MMP inhibi-
tion by doxycycline alters the asymmetric deposition of collagen,
elastin and degradation of fibrin under pulsatile flow conditions.
We assessed the fibrin content of the tissues, in the presence and
absence of doxycycline at the concentration of 10 µg mL−1, in the
same range of blood serum concentrations of patients that were
clinically treated to manage aneurysm growth.[55] We found that
the accelerated fibrin degradation was halted upon doxycycline
treatment on the tissue backside, reaching the same levels as for
the tissues facing the high velocity flow (Figure 5b,c; FigureS9,
Supporting Information).
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Figure 6. TheMMP inhibitor doxycycline enhances collagen I and elastin accumulation in both of the engineered SMCs tissues. Biochemical assay of total
a) collagen and b) elastin revealed higher assembly of collagen within the backside tissues and higher elastin content within the frontside tissues, but the
effect of low-velocity flow reduced in the presence of doxycycline (10 µgmL−1, yellow-shaded bars) after 3 weeks of culture. Comparative immunostaining
of c) collagen I (magenta) and d) elastin (red) in the presence and absence of doxycycline. Fibronectin was visualized not by immunostaining, but by
supplementing labeled Alexa Flour 488 human plasma fibronectin (green) to the cell culture medium.[38] Relative signal intensity analysis of e) collagen
I and f) elastin showed the same trend as found in biochemical assays. Number of biological replicates was 3; ≥5 images were analyzed. All tissues have
been treated according to the timeline given with the Figure 4e. Scale bars 50 µm. See also Figures S10–S12, Supporting Information, for single-channel
confocal images of collagen I, III, and elastin, respectively.
To quantify how ECM formation is affected by the presence
of doxycycline (10 µg mL−1), we quantified collagens and elastin
(N = 6 each). In the doxycycline-treated tissue’s frontside com-
pared to the non-treated controls, the total collagen content is
≈2.5 higher (Figure 6a). In the collagen-rich backsides, doxycy-
cline treatment further increased the collagen content by ≈1.4-
fold (Figure 6a). The same trend is seen using the pixel-by-pixel
analysis of the ECM images (Figure 6c,e; Figure S10, Supporting
Information), yet less pronounced.
Remarkably, even though collagen III did not show flow-
dependent difference in the non-treated group, its deposition
in the tissues facing the front was significantly increased in
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the presence of doxycycline (p < 0.0001, Figure S11, Support-
ing Information). Finally, doxycycline significantly improved
the elastin content on both sides and reduced the asymmetrical
difference to nonsignificant value (Figure 6b,d,f; Figure S12, Sup-
porting Information). Our findings thus show that doxycycline
treatment did suppress the asymmetry, and slightly improved the
total elastin deposition in contrast to the controls, thus confirm-
ing the counterregulatory roles of MMPs in disrupting elastin
assembly. Taken together, our data suggest that TIMPs are the
major drivers that steer the differential ECM compositions in our
de novo grown tissues. These findings further highlight the ne-
cessity to include pulsatile flow conditions in the in vitro studies.
It is also remarkable that the de novo grown tissue cultured for 3
weeks under flow conditions effectively recapitulate ECM com-
positions found in healthy and pathological human blood vessels.
Besides, these data once more point to the major role of flow on
SMCs and their capacity to tweak the TIMPs/MMPs balance to
assemble and remodel ECM.
We also tested doxycycline at a concentration of 40 µg mL−1,
the same concentration that has been used in prior animal
and in vitro cell studies.[53,54,56,57] At such a high concentration,
doxycycline completely prevented SMCs to remodel and digest
the fibrin hydrogel in the tissue (Figure S13, Supporting Infor-
mation). Additionally, a comparatively small amount of ECM
was produced (Figure S13, Supporting Information) and the
cells were not able to expand and migrate out from the fibrin
matrix, although after removing the drug cells were recovered
and expanded (Figure S14, Supporting Information). Our data
thus suggest that doxycycline in such animal and in vitro studies
might have been overdosed and completely suppressed the SMCs
activity.
3. Discussion
While a number of pump-driven in vitro fluidic cell culture
models have been proposed for vascular research,[15,17,58] we
introduce here a platform that can impose simultaneously two
distinct pulsatile flow conditions on bioengineered 3D tissues
(Figure 1). Our device is different from other often utilized cell
culture models[19,20] that use the bottom of dish to impose a flow
stress on 2D culture of cells. Here, our tissue-engineered flap was
mounted perpendicular to the bottom, thus facing and redirect-
ing the flow, thereby exposing the tissues to horizontal and nor-
mal force components, which are poorly mimicked in common
model devices (Figure 1a). While this design allows to simulta-
neously investigating the impact of two flow regimes, creating
comparable flow conditions within tubular 3D bioengineered tis-
sues is much more difficult to accomplish. For instance, a prior
study showed that laminar pulsatile flow induced the assembly
of elastin on the luminal side of the tubular engineered vessel,[37]
but no data were provided on how more turbulent flow patterns
might impact the outcome. Because of this novel design, our
device enabled us to show the differential effects of flow on the
opposing sides of in vitro grown 3D tissue and we quantified flow
velocities and shear wall stresses (Figure 2). Since the EC layer is
disrupted in pathological vascular tissues thereby exposing the
SMCs to disturbed flow,[59] we studied here the direct effect of
flow on the de novo tissue growth of SMCs. Human SMCs were
seeded into PGA-P4HB-fibrin 3D scaffolds and cultured for 3
weeks under pulsatile flow conditions. As native SMCs are not
equipped with shear sensors, like ECs, much less is known how
flow exposure might alter the physiology of SMCs. For the first
time in an in vitro 3D engineered tissuemodel, we show here that
altered fluid flow conditions can have major impact on the ability
of SMCs to assemble and remodel ECM (Figure 4). These overall
changes in ECM composition are accompanied by significantly
upregulated levels of 𝛼-SMA at the gene and the protein expres-
sion (Figure 3), indicating increased redifferentiation toward the
SMC phenotype when exposed to high-velocity flow as discussed
before. In the high-velocity front versus low-velocity backside of
the flap, the ECM is significantly enriched in elastin, while the
collagen I content is decreased (Figure 4a,c,d,e). In contrast and
at first surprising, COL1A1 and ELN gene expression is mostly
equal in the front and backsides of the flap (Figure 4g). Evenmore
drastic, the COL3A1 gene expression is increased fourfold in the
front, yet the total collagen content of ECM in the back is signif-
icantly higher in the back (Figure 4a). Taken together, this sug-
gests that the proteolytic activities as tuned by the flow-exposed
SMCs in the front versus back might be significantly different as
verified here (Figures 5 and 6).
The differential changes of ECM compositions as summarized
in Figure 7, namely increase assembly of collagen and loss of
elastin in these de novo grown tissues (Figure 4), thus recapitu-
late ECM transformations reported from vascular aneurysm and
atherosclerotic tissues.[10,60] Our de novo grown tissues, thus, as-
sembled an ECMunder pulsatile high-velocity flow that displayed
some hallmarks of those characteristic for healthy arteries, even
though SMCs under healthy physiological conditions are not di-
rectly exposed to flow. This suggests that the elastin production
per se might not be affected by exposure of SMCs to high velocity
flow, but that elastin degradation is only induced when SMCs get
exposed to disrupted low velocity flow.
Shifting the TIMPs/MMPs balance is known to play a major
role in vascular diseases such as aneurysm, atherosclerosis,
hypertension, calcification of heart valves, and of other valvular
remodeling diseases.[45,61,62] Even though different clinical and
animal studies showed a higher MMP expression and activity in
pathologic arterial wall tissues,[45,63,64] we did not find significant
changes in MMPs gene expression of SMCs tissues in the front
and backsides (Figure 5a). Instead, the expression ofTIMPs 1 and
3 was significantly upregulated in the tissues facing the pulsatile
traveling wave, which we now propose is protecting ECM degra-
dation. As this suggests enhanced proteolytic activity within
the backside of the tissues, we further tested this hypothesis by
supplementing the medium with the doxycycline, which is a
general MMP inhibitor.[49] Indeed, doxycycline halted the pro-
teolytic activity of SMCs as shown by a fibrin degradation assay
(Figure 5b), thus confirming our conclusion that a relatively
higher elastase activity coupled with a lower TIMPs activity
disrupts elastin assembly in the backside (Figure 4). We further
propose that the relatively higher gene expression of FN and
FNB-1 (Figure 4g) could further enhance the elastin assembly in
the front.[42,43]
Most importantly with respect to clinical applications of metal-
loproteinase inhibitors, treatment with doxycycline resulted in an
overall increase in collagen and elastin deposition and reduced
the differential effect of our two flow conditions on the total
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Figure 7. Summary of relative ECM compositions as deposited in de novo grown tissues in response to different flow regimes, as well as in the presence
of the MMP inhibitor doxycycline, a drug that is clinically used to treat aneurysm and atherosclerosis plaques. In the upper part, the top views of the
curved engineered tissues attached to the edge of the device platform are shown.
collagen and elastin ECM content (Figure 6). In this context, it is
interesting to note the 5.6-fold upregulated TIMP-3 expression
in the front versus the backside (Figure 5a), as TIMP-3 is the only
member of TIMPs that inhibits the procollagen N-proteinase
(ADAMTS-2). ADAMTS-2 is responsible for cleaving procolla-
gen C-propeptides as required for collagen fibrillogenesis.[47,48]
This suggests that the higher expression of TIMP1-3 protects the
assembled ECM fibers, while at the same time, inhibits the as-
sembly of collagens in the frontside of the flap. Remarkably, doxy-
cycline treatment reduced the relative expression of TIMP-3 from
5.6-fold to 1.5-fold (front compared to backside), thereby confirm-
ing the role of TIMP-3 on collagen assembly in our drug-treated
tissues.
Two possible causes of aneurysm rupture are well described
in the literature:[3,10,25,26,45,59] i) increased proteolytic activity of
the cells in vessel walls; and ii) progressive remodeling and im-
balance of the ECM content. Since doxycycline was subjected to
several human clinical and animal preclinical studies to treat a
variety of vascular diseases[50–52] and showed controversial effects
in the management and prevention of aneurysm,[28,45] we finally
asked what can be learned from our model regarding the effi-
cacy of doxycycline. Doxycycline switched the symmetric ECM
fibril deposition of collagen III to asymmetric deposition, with
decreased levels at the back of the tissues (Figure S11, Support-
ing Information). Previous in vitro experiments suggested that
alterations of the tropocollagen types I and III ratio change the
mechanical properties of the heterotypic collagen fibrils with dif-
ferent mixing ratios of tropocollagen III to I, whereby coassem-
bly of collagens I and III caused the fibrils to be thinner with a
shorter D-banding than pure collagen I, resulting in a higher elas-
tic modulus.[65] Taken together with our data, this suggests that
the accumulation of collagen I[11] ultimately decreases the colla-
gen III/I ratios (Figure 7), implying that this might contribute
to a stiffening of the vessel wall. Collagen III/I ratios were re-
ported to be higher in soft and elastic tissues compared to stiffer
tissues[65] and patients with collagen III deficiency have an in-
creased risk of cerebral aneurysm rupture.[66] Our findings shed
new light into the controversial discussion of the efficacy of doxy-
cycline, which we now propose depends on the progressive stage
of vascular diseases. In a highly flow-dependent response, doxy-
cycline treatment can have an either positive or negative effects
on vascular ECM remodeling (Figure 7). On the beneficiary side,
doxycyclinemight halt the ECM degradation by reducing the pro-
teolytic activity of SMCs, as seen clinically,[61] and thus protect
the existing ECM fibrils. On the negative side, treatment with
doxycycline could increase the collagen I content and thereby re-
duce the collagen III/I ratio in the presence of disturbed low-
velocity flow, which subsequently might lead to a stiffening and
loss of elasticity of the vessel wall and thereby increase the risk of
rupture.
In conclusion, treating our tissue engineered flaps with doxy-
cycline might provide critical new insights why the clinical data
are ambivalent.[28,45] Our data suggest that the critical balance of
beneficiary and harmful effects might depend on the progressive
stage of vessel wall pathology. Aneurysm therapy with general
MMP inhibitors in late stages of the disease, when themajority of
elastic fibrils have been already degraded, might not be effective:
doxycycline treatment might then even stiffen the vessel wall by
changing the collagen III/I ratio, thus enhancing the risk of wall
rupture. However, in early stages, where the majority of elastic
fibrils are intact, doxycycline might prevent degradation of exist-
ing ECM and slow down the disease progression. Thus, prior to
administration of doxycycline or other MMP inhibitors, we pro-
pose that the stage of the disease must be screened carefully to
prevent such an adverse effect and to improve the therapeutic
outcome. Beyond these significant insights into how SMCs re-
spond to different flow conditions, our data also show that our
device is well suited to test the efficacy of drugs on tissues grown
from human cells, and that mechanisms leading to side effects
can, thus, be studied under in vitro conditions. When combined
with autologous cells, this illustrates how the platform can be ex-
ploited in the future for drug efficacy studies for personalized
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medicine applications, giving mechanistic insights into how dif-
ferent therapeutic interventions might affect tissue growth and
ECM assembly. It thus has significant potential for applications
in personalized and precision medicine.
4. Experimental Section
Scaffold Preparation and Device Assembly: Commercially available non-
woven PGA scaffolds (thickness 1.0 mm; specific gravity 70 mg cm−3; Cel-
lon, Luxembourg) were coated with 1% P4HB (MW: 100 000; Tepha, Inc.,
MA, USA) in tetrahydrofuran (Sigma-Aldrich, Switzerland).[67] Thereafter,
the scaffold was cut into rectangular pieces (5 mm × 18 mm) that were
fixed on one end to the inner wall of a petri dish, and on the other end to
a post 1 cm inside the dish using an UV optical glue (Norland Products,
Inc., NJ, USA) according to the detailed plan given in Figure S1, Supporting
Information, to reproduce the curvature. The final constructs were steril-
ized using a mixture of 10% hydrogen peroxide in 70% ethanol and UV
light for 1 h. The installed scaffolds were then washed at least three times
with sterile phosphate-buffered saline (PBS), followed by overnight soak-
ing in culture medium consisting of Dulbecco’s modified Eagle’s medium
GlutaMax (Invitrogen, USA) supplemented with 10% fetal bovine serum
(Invitrogen) before cell seeding. In the second scenario and to assess the
overall ECM content of tissues facing either the laminar or the disturbed
flow quantitatively, two similar sheets of PGA-P4HB scaffold were placed
together and installed into the culture dish using the same configuration
and sterilization methods as mentioned above. To carefully analyze the
tissue formation processes at the front and backsides, the flaps consisted
of two scaffold sheets sandwiched on each other, such that they could be
peeled apart after cell culturing and processed separately for proteins and
gene expression analyses.
Flow Velocity Measurements in Orbital Shaker Platform Using Particle
Image Velocimetry: The velocity of the flow circulating around the petri
dish in a horizontal plane 3 mm above the bottom of the petri dish was
measuredwith illuminating laser light sheet (550 nm) according to the pre-
viously described method.[20] To do this, fluorescent polyethylene micro-
spheres (38–45 µm, Cospheric, USA) were dispersed in water and placed
into the petri dish at height of 10 mm. The entire setup, including laser
light source and camera, was assembled on the orbital shaker platform to
capture the flow and not the overall movement of petri dish. A high-speed
camera was used to capture images at different exposure times. To
estimate the velocity in the region of interest (near the wall, back and front
of scaffolds), strike length of particle track was measured in images. The
velocity of particle was calculated by using an exposure time of 25 ms with
an acquisition rate of 37 images per second. The average velocity at each
time point was calculated by averagingmeasured particles velocities in the
region of interested. Also, to visualize the particle movements in the whole
field of view (Figure 1d), high-speed images with acquisition rate of 110
image per second and 2 ms exposure time were captured, then superim-
posed and temporary color-coded using ImageJ software and presented in
quarter of one cycle.
Computational Modeling: ANSYS Fluent (ANSYS, Inc.) was used to
computationallymodel the 3D unsteady two-phase flow inside the orbitally
shaken petri dish, that is, a traveling water wave in contact with the gas
phase as confined by the circular geometry of the petri dish. The flap ge-
ometry was modeled as a fixed solid boundary with average thickness of
800 𝜇m mounted to the inside wall of the petri dish which was initially
filled with 8 mm height of water as the liquid phase while air occupied the
rest of the volume. The commonly used k − 𝜖 turbulent model was em-
ployed to simulate circular turbulent flow,[30] where k represents turbulent
kinetic energy and 𝜖 represents the turbulent dissipation to solve the turbu-
lent flow governing equations, that is, Reynolds-averaged Navier–Stokes
equations. By using a frame as a reference, motion of the orbital shaker
was prescribed for the whole domain representing motion of the dish with
respect to a static observer. Movement of the shaker was exerted to the
whole domain with dynamic mesh interface in the software package. User-
defined function written in C++ language was compiled to implement the
rigid body motion of the shaker. The free-surface between the two phases
was captured using volume of fluid method in which single set of momen-
tum equations is solved for both phases and volume fractions are tracked
through the domain. To represent the time-dependent shape of the inter-
face, a geometric reconstruction scheme was adopted according to the
ANSYS Fluent Theory Guide (release 15.0.2013; ANSYS, Inc.). Water was
modeled with a density of 𝜌 = 998
kg
m3
and viscosity of 𝜂 = 1e − 3 Pa s




and 𝜂 = 1.8e− 5 Pa s. No slip condition was applied to all wall
boundaries.
Cell Isolation, Seeding, and Culturing Condition of Scaffolds: Human ve-
nous vascular SMCs were harvested from human vena saphenous magna
donors (healthy volunteer women, 40–60 years old) according to the
Zurich University Hospital ethical approval (KEK-Stv-21-2006) and ex-
panded as described before.[32] Cells with passage number between 4
and 8 were used in this study. Cell seeding was performed using fibrin
gel as carrier as previously described.[68] Briefly, cells were defrosted, ex-
panded, and trypsinized based on standard cell culture protocols. Then
cells were resuspended in a sterile bovine thrombin (Sigma, USA) solu-
tion in PBS (10 IU thrombin per mL). Fibrinogen solution was prepared by
dissolving 14mg of lyophilized bovine fibrinogen powder (Sigma) equal to
10 mg mL−1 active fibrinogen into the culture medium then was sterilized
using 0.21 µm sterile syringe filter. Subsequently, the cells in the thrombin
solution were added to a sterile bovine fibrinogen in equal volume. After
carefully mixing, the fibrin solution containing the cells was dripped onto
the scaffold to fill the scaffold porosities. For double-layer constructs, dou-
ble number/volume of cell-fibrinogen solution added to scaffolds and let
them set. The coagulation time of the fibrin gel was determined to vary
from 20 to 40 s. After the seeding procedure, constructs were kept for
polymerizing for 15 min in the incubator before addition of the medium.
All the constructs were placed in static conditions for 24 h; at this point,
the mechanical stimulation was started using an orbital shaker (VWR In-
ternational, USA). The rotation radius of the shaker was 19 mm and the
rotation speed was set to 1.5Hz (90 rpm). Culturemediumwas exchanged
every 3 days, and the incubation was performed at 37 °C, 10% CO2. Cell
passages from 4 to 8 were used in this study.
Total Collagen Analysis: The Sircol soluble collagen assay kit (biochem-
ical, colorimetric method from Biocolor, UK) was used to analyze the total
collagen content of tissues.[69] To do this, the tissue samples were cut
and washed with PBS. The excess liquid was taken by a paper tissue and
the weight was measured. Subsequently, the collagen was solubilized by
adding 1 mL pepsin solution (0.5 mgmL−1 in 0.5 M acetic acid) at 4 °C for
24 h. To graph the standard curve, the same procedure was conducted to a
blank (10 mg PGA-fibrin unwoven meshwork in 0.1 mg mL−1 pepsin solu-
tion) and known collagen concentration of 5, 10, and 15 µg. The solutions
were then neutralized by adding 100 µL neutralizing solution. Thereafter,
a PEG solution was added for 24 h at 4 °C to concentrate collagen accord-
ing to the manufacturer’s protocol followed by samples centrifugation at
10 000 × g for 10min to isolate the collagen pellets. To each tube, 1 mL Sir-
col dye reagent (sirius red) was added and mixed well for 30 min and then
spun for 10 min at 10 000 × g. At this step, collagen will bind to sirius red
dye and precipitate. To remove the unbounded dyes, the precipitate was
washed with ice-cold acid-salt solution and centrifuged again to collect
the pellets. Finally, the bonded dyes to collagen were dissolved in 250 µL
of alkali reagent and transferred to 96-well plate and measured at 555 nm
with Tecan microplate reader (Switzerland). The collagen concentration
was calculated based on standard curve and presented in micrograms per
milligram of tissue weight.
Total Elastin Analysis: The Fastin Elastin Assay kit (Biocolor) was used
to analyze the total elastin content of scaffolds and tissues according to
the manufacturer protocol.[70] Briefly, samples were weighed and digested
in 0.25 M oxalic acid at 100 °C for 1 h. For animal specimens, tissues were
disintegrated using an ultrasound homogenizer to improve the oxalic acid
digestion. To draw the standard curve, a blank (PGA-fibrin scaffold) and
gradient of known concentration of soluble 𝛼-elastin were processed sim-
ilarly. All solutions were filtered by 0.21 µm syringe filter to minimize the
effect of running particles in future steps. After elastin dissolution, it was
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precipitated at 4 °C for 15 min using precipitating reagent and centrifuged
at 10 000 × g for 10 min to separate the pellets. Then the pellets were
suspended in 1 mL dye reagent and mixed for 90 min followed by 10 min
of centrifugation at 10 000 × g to separate the pellets. Finally, the pellets
dissolved in 250 µL dye dissociation reagent and measured by microplate
reader at 513 nm to calculate the elastin concentration. The elastin con-
centration was calculated based on the standard curve and presented in
micrograms per milligram of tissue weight.
Fluorescence Immunostaining and Fibronectin Visualization: For fluo-
rescence immunostaining, tissues were washed with PBS and then fixed in
4% paraformaldehyde in PBS for 30 min. Nonspecific adsorption of anti-
body was prevented by albumin preincubation with bovine serum albumin
(2%w/v, 30min). After washing the samples three times with PBS, tissues
were incubated with primary antibodies according to Table S1, Support-
ing Information. Samples were then washed three times with Dulbecco’s
phosphate-buffered saline (DPBS) and treated with the secondary anti-
body (goat anti-rabbit Alexa Fluor 633 or goat anti-mouse Alexa Fluor 633
all from Invitrogen) with dilution of 1:500 DPBS for 1 h at room temper-
ature. Nonspecific antibody binding of primary and secondary antibodies
was controlled by blank samples (negative control) or animal or human
tissues specimens that present antigens (positive control) as exemplified
for elastin in Figure S15, Supporting Information. Cell nuclei were stained
by 4′,6-diamidino-2-phenylindole (2 µg mL−1, 10 min). Samples were fi-
nally washed three times with PBS. For visualization of human plasma
fibronectin, Alexa Fluor 488-labeled human plasma fibronectin was added
to the culture medium (5 µg mL−1) during the culture period as described
before.[71] Labeled fibronectin gets incorporated by cells into their fibril-
lar fibronectin ECM networks. The samples were imaged using a confocal
microscope (Olympus FV1000, Japan).
Image Analysis: Pixel-by-pixel signal intensity analyses were performed
using image histograms while keeping the imaging conditions identical
for samples needing to be compared. Such analyses were performed to
compare collagen type I, III elastin, and fibrin density in front and back-
sides of the tissues. The average mean intensities from selected parts of
an image were measured using ImageJ to plot graphs as shown in dif-
ferent figures. It should be noticed that the autofluorescence of partially
degraded PGA fibers seen in various images (after 3 weeks) can be excited
and imaged at 633 nmwith rather low laser intensity (Figure S16, Support-
ing Information). To overcome this issue, the parts of images were man-
ually selected and analyzed in which there were no PGA fibers in the field
of view as shown in Figure S17, Supporting Information. In this process,
the fibronectin channel was used as a guide to choose areas with ECM
on uneven surface of samples. For the representative images given in the
figures, 20 images were stacked from the surface to 50 µm in depth to in-
clude and visualize maximum accessible surface. Cross-sectional confocal
images were taken by mounting the sample in vertical direction to the field
of view.
RNA Extraction and Reverse Transcription: Total RNA was extracted
using the Rneasy RNA isolation kit and column (Qiagen) following the
manufacturer’s instructions. Reverse transcription was performed for
each sample in 50 µL reactionmixture containing 40 µL of RNA in RNAase-
free water (40 ng µL−1), 8 µL of iScript advanced reaction mix, and 2 µL
of iScript Advanced reverse transcriptase all from Bio-Rad. The conditions
for the reverse transcription were as follows: 46 °C for 20 min, followed by
95 °C for 1 min.
Quantitative Real-Time PCR: The resulting cDNA was amplified in du-
plicate by quantitative real-time PCR in 10 µL reaction mixtures with 200 ×
10−9 m of each specific primer and 1× Fast Syber Green qPCR Master Mix
(Life Technologies). For the amplification reaction, QuantStudio 7 from
Applied Biosystem was used. The amplification program was set as fol-
lows: 95 °C for 5 min, followed by 45 cycles at 95 °C for 10 s, 60 °C for 15 s,
72 °C for 20 s. The glyceraldehyde 3-phosphate dehydrogenase and 18S
gene expression was used for sample normalization and the Excel soft-
ware was used for the comparative quantification analysis. The primers
were designed using the free online software Primer3. The sequences were
tested for their specificity by performing a BLAST alignment (basic local
alignment search tool) on the human respective mRNA.
Statistics: Data were compared using one-way ANOVA with post hoc
Bonferroni test (OriginPro 9). Error bars if any are standard deviation un-
less noted in image caption.
Supporting Information
Supporting Information is available from the Wiley Online Library or from
the author.
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